The in vitro antibacterial spectrum of gatifloxacin was compared with those of ciprofloxacin and ofloxacin. Gatifloxacin was two-to four-fold more potent than comparator quinolones against staphylococci, streptococci, pneumococci and enterococci (gatifloxacin MIC 90 
Introduction
The quinolone class of antimicrobial agents has a wide antibacterial spectrum, though differences exist between compounds in their potency against Gram-positive bacteria, non-fermentative bacteria and anaerobic organisms. Gatifloxacin ((Ϯ)-1 cyclopropyl-6-fluoro-1, 4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid sesquihydrate) is a fluoroquinolone with a methoxy side chain at the C-8 position (C8-OMe). Several biological effects have been attributed to this side chain.
First, it appears to impart enhanced inhibitory activity against the DNA gyrase of Gram-positive bacteria, 1 and hence, increased potency against Gram-positive bacteria. In addition, the side chain increases the bactericidal action of quinolones, particularly against gyrA mutants.
2,3 The C-8 methoxy side chain may also decrease the rate of development of resistance to quinolones, 2 and, moreover, reduce quinolone phototoxicity. 4 In this study, we determined the activity of gatifloxacin in more than 60 bacterial species and compared it with those of ciprofloxacin and ofloxacin.
Bacterial strains
All bacterial strains used in this study were clinical isolates obtained from numerous sources of broad geographical distribution. Isolates were maintained frozen in liquid nitrogen.
Growth inhibitory activity
MIC values were determined by an agar dilution method in accordance with the procedures outlined by the NCCLS. 2 for 72 h; Bordetella spp. in ambient air for 72 h; Bartonella spp., in 5% CO 2 for 5 days), or in a microaerophilic atmosphere with the Campy-Pak system (BBL Microbiology Systems) for C. jejuni, or for 48 h in an anaerobic atmosphere for anaerobes. The MIC was defined as the lowest concentration of drug that prevented visible growth.
Susceptibility tests with Mycobacterium spp. were performed by a macrobroth dilution method in 7H9 broth (Difco) and 2 ϫ 10 7 cfu/ml final bacterial inocula. The tubes were incubated at 35°C in 5% CO 2 . Inhibition of growth was monitored for 3 weeks although growth controls almost always demonstrated very heavy growth after 7 days' incubation. The MIC was defined as the lowest concentration of drug that inhibited visible growth after 3 weeks' incubation. All work involving mycobacteria was done under a biological safety cabinet in a high-containment facility.
The MICs for Chlamydia trachomatis and Chlamydia pneumoniae were determined using, respectively, McCoy (ATCC) and HL 6 cells (Washington Research Foundation, Seattle, WA, USA) in a microtitre format. Chlamydial suspensions prepared in a maintenance medium [Eagle's minimal essential medium (Gibco) supplemented with fetal bovine serum for C. trachomatis and Iscove medium for C. pneumoniae] contained approximately 100-1000 inclusionforming units per mL, with 0.05 mL of the suspension added per well. The plates were centrifuged at 1000g for 60 min. Two-fold serial dilution of the quinolones in maintenance medium was added (100 L). Plates were incubated for 48 h (for C. trachomatis) or 72 h (C. pneumoniae) in 5% CO 2 and then fixed with methanol and stained with 0.02 mL of fluorescein-conjugated monoclonal antibody specific to the chlamydial lipopolysaccharide. The presence of chlamydial inclusion bodies was detected via an inverted fluorescent microscope at ϫ100 magnification. The MIC was defined as the lowest drug concentration with no observable inclusion bodies.
MICs for Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum were performed by a microbroth dilution method. The test medium was PPLO medium (Difco) supplemented with yeast extract, horse serum and either dextrose (for M. pneumoniae), arginine (for M. hominis) or urea (for U. urealyticum). Two-fold serial dilutions of the quinolones were prepared in the test medium. The inoculum contained 10 4 -10 5 colour-changing units (CCU) per mL, and 100 L of the adjusted inoculum was added to the 100 L of the diluted drug in each well. A CCU is the minimum inoculum required for growth as indicated by a colour change in phenol indicator. MIC was defined as the lowest dilution of antibiotics that inhibited growth as indicated by the lack of a colour change, relative to the growth control with colour change.
Susceptibility testing of Borrelia burgdorferi was done in 48-well microtitre plates using BSK II medium supplemented with 6% haemolysed rabbit serum. Quinolones were two-fold serially diluted in growth medium. Two-to 3 day growth of B. burgdorferi was added to a final inoculum of approximately 1 ϫ 10 5 cfu/mL. The plates were incubated for 4 days at 34°C in a microaerophilic atmosphere (Campy-Pak) and then 10 L samples were removed and examined under dark-field microscopy at ϫ200 magnification. The MIC was defined as the lowest drug concentration that inhibited all growth per 10 fields examined.
The interpretative MIC breakpoints used to analyse the data in this study were those recommended by the NCCLS. 
Results and discussion

Gram-positive aerobic bacteria
Gatifloxacin was about two-to four-fold more potent than ciprofloxacin and ofloxacin against methicillin-susceptible (MS) strains of Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus and Staphylococcus saprophyticus, with modal MIC 90 s of 0.12 mg/L for gatifloxacin and 0.25-0.5 mg/L for ciprofloxacin and ofloxacin (Table I) . These quinolone MIC 90 values increased Ͼ16-fold against methicillin-resistant (MR) strains of staphylococci. Based on their interpretative criteria for susceptibility, all of the MS S. aureus strains were susceptible to the three quinolones. In contrast, 51%, 55% and 78% of the 58 MR S. aureus strains had MICs at or below the susceptible breakpoint for ciprofloxacin, ofloxacin and gatifloxacin, respectively. Nevertheless, since clinical resistance to ciprofloxacin developed quickly among MR S. aureus, 7, 8 the utility of gatifloxacin against this group of organisms may depend also on the rate of resistance development to gatifloxacin. We have reported that the frequency of selecting for less susceptible variants of MR S. aureus by gatifloxacin was 100-fold less than by ciprofloxacin. 9 It remains to be determined whether these in vitro observations on gatifloxacin will translate to its clinical usefulness in the treatment of MR S. aureus infections.
Gatifloxacin was four-to eight-fold more potent than ciprofloxacin and ofloxacin against streptococci (Table I) . The MIC 90 s of gatifloxacin were 0.5 mg/L for the majority of streptococcal strains tested, including penicillin-intermediate and -resistant strains of pneumococci, and 1 mg/L for Streptococcus sanguis. The ciprofloxacin and ofloxacin MIC 90 s for streptococci were generally 2-4 mg/L.
Gatifloxacin was active against Enterococcus faecalis (MIC 50 and MIC 90 of 0.5 and 1 mg/L), and against some strains of Enterococcus faecium (MIC 50 and MIC 90 of 1 and 4 mg/L). Ciprofloxacin and ofloxacin had lower potency against enterococci.
Gatifloxacin was the most potent agent against L. monocytogenes, G. vaginalis and Gram-positive bacterial species that are intrinsically resistant to vancomycin (i.e. Leuconostoc, Lactobacillus and Pediococcus spp.) (Table II) . All three quinolones were less potent against Pediococcus spp. For the most part, gatifloxacin was active against many imipenem-resistant strains of Corynebacterium spp., including strains of Corynebacterium jeikeium and Corynebacterium urealyticum (formerly CDC group D2).
Gram-negative aerobic bacteria
The quinolones were very active against members of the family Enterobacteriaceae (Escherichia coli, Klebsiella spp., Citrobacter spp., Enterobacter/Pantoea spp., Serratia marcescens, Salmonella spp., Shigella spp. and Yersinia spp.), with lesser activity against Providencia spp. (Table I) . Gatifloxacin (MIC 90 s, 0.06-0.5 mg/L) was often two-fold less potent than ciprofloxacin, and the same as or two-fold more potent than ofloxacin against the Enterobacteriaceae. The quinolones were less potent against Providencia rettgeri (MIC 90, 1, 2 and 4 mg/L of gatifloxacin, ofloxacin and ciprofloxacin, respectively), and Providencia stuartii (MIC 90 , 4 mg/L for gatifloxacin compared with Ͼ16 mg/L for ciprofloxacin and ofloxacin, respectively). Gatifloxacin and ofloxacin were two-to four-fold less potent than ciprofloxacin against Pseudomonas aeruginosa. (Table I) . While gatifloxacin and ciprofloxacin had comparable potencies (MICs Ϸ 1 mg/L) against B. burgdorferi and Bartonella spp., they were about two-to eight-fold more potent than ofloxacin against these species (Table II) .
Of the three quinolones, gatifloxacin (MICs, 0.13 mg/L) was the most potent against C. trachomatis and C. pneumoniae, being eight-to 16-fold more potent than ofloxacin and ciprofloxacin (Table I) . Thus, given its higher intracellular accumulation in eukaryotic cells, 10, 11 gatifloxacin should be very effective against these pathogenic organisms.
Based on MIC 50 values, gatifloxacin was four-to eightfold more potent than ciprofloxacin and ofloxacin against ureaplasma, 10-fold more potent against M. pneumoniae and eight-to 16-fold more potent against M. hominis (Table I ). The MICs of gatifloxacin for mycoplasma were р0.25 mg/L, while they were much higher (MIC range, 0.5-4 mg/L) for ureaplasma. While ureaplasma might be intrinsically less susceptible than mycoplasma to quinolones, one primary contributing factor for the higher MICs could be the use of urea as the indicator in ureaplasma testing. Urea supplementation results in an acidic pH, a condition known to affect adversely the activity of quinolones. 12 Thus, it is likely that quinolones are intrinsically more active against ureaplasma than these MICs suggest.
Mycobacterium spp.
Gatifloxacin was active against Mycobacterium tuberculosis, being eight-to 16-fold more potent than ciprofloxacin and ofloxacin (Table I) . Though gatifloxacin was less potent against Mycobacterium avium-intracellulare (MAI) strains (Table II) , it was again four-fold more active than comparator quinolones. Interestingly, although complete inhibition of growth was achieved at 2 mg/L of gatifloxacin in three MAI strains, partial inhibition of two additional MAI strains was noted.
Anaerobic bacteria
Unlike ciprofloxacin and ofloxacin, which were active only against Clostridium perfringens and Propionibacterium acnes (MIC 90 s, 1 mg/L), gatifloxacin was active (MICs, 0.5-2 mg/L) against Bacteroides fragilis, Clostridium difficile, Peptostreptococcus spp. and other Bacteroides spp. (Tables I and II) . Ciprofloxacin and ofloxacin MIC 90 s for B. fragilis and C. difficile were Ͼ 8 mg/L. With the exception of the five Fusobacterium varium (gatifloxacin MICs, 2-4 mg/L), gatifloxacin MICs were р0.5 mg/L for the other Fusobacterium spp. In summary, gatifloxacin has a broad antibacterial spectrum. Compared with ciprofloxacin and ofloxacin, gatifloxacin has notably enhanced potency against contemporary Gram-positive aerobic bacteria, S. maltophilia, anaerobic bacteria, chlamydia, mycoplasma/ureaplasma and mycobacteria. 
